The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

US stocks fell on Tuesday, with the S&P 500 snapping a six-day winning streak as bond yields crept higher, with gloomy comments from JPMorgan's boss dampening the mood.

Japan's bond yield surge hints at global market risks. See how it impacts U.S. Treasuries, the yen, and top investments like ...

Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi , an innovative global healthcare company, and Regeneron , a ...

Fed officials say debt downgrade complicates inflation outlook, Nvidia CEO discusses China chip ban, JPMorgan’s investor day, ...

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand ...

The US’s credit rating took a hit on Friday, after Moody’s downgraded the country’s AAA rating. And then yesterday, bond ...

Mufg Securities Americas Inc. made a modest splash in the biotech pool, acquiring 1,554 shares of Regeneron Pharmaceuticals ...

The Moody’s announcement sent the yield on a 30-year Treasury bond to a high of 5.01% at one point on Monday. Bond yields ...

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and ...